Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

Trial Profile

A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Nivolumab (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Bladder cancer; Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 25 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 14 May 2018 Status changed from planning to not yet recruiting.
    • 14 Nov 2017 According toDaiichi Sankyo media release,at the 2017 San Antonio Breast Cancer Symposium (SABCS), San Antonio and the 59th Annual Meeting of the American Society of Hematology (ASH)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top